Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANV001
MIFTS: 47

Anovulation

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Anovulation

About this section

MalaCards integrated aliases for Anovulation:

Name: Anovulation 12 54 43 15 71

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3781
MeSH 43 D000858
NCIt 49 C34388
SNOMED-CT 67 34571000
UMLS 71 C0003128
Sources

Summaries for Anovulation

About this section
Disease Ontology : 12 An ovarian disease that is characterized by the absence of ovulation.

MalaCards based summary : Anovulation is related to galactorrhea and hyperprolactinemia. An important gene associated with Anovulation is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Prolactin Signaling Pathway. The drugs Acetylcysteine and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include ovary, pituitary and breast, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Anovulation is when the ovaries do not release an oocyte during a menstrual cycle. Therefore, ovulation... more...

Sources

Related Diseases for Anovulation

About this section

Diseases related to Anovulation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 galactorrhea 31.3 PRL IGF1
2 hyperprolactinemia 31.1 SHBG PRL INS IGF1 GNRH1 CGA
3 premenstrual tension 31.0 SHBG GNRH1
4 ovarian cyst 30.8 PRL GNRH1 CYP19A1 CGA
5 infertility 30.8 SHBG PRL GNRH1 FSHR FSHB CYP19A1
6 precocious puberty 30.7 GNRH1 CYP21A2 CYP19A1
7 diabetes insipidus, neurohypophyseal 30.5 PRL IGF1 GNRH1
8 diabetes insipidus 30.5 PRL INS CRH
9 placenta disease 30.5 INS CRP CGA
10 ovarian hyperstimulation syndrome 30.5 SHBG INS GNRH1 FSHR FSHB CYP19A1
11 endometriosis 30.4 IGFBP1 GNRH1 FSHR CYP19A1 CGA
12 pituitary gland disease 30.4 PRL INS IGF1 GNRH1 CRH CGA
13 empty sella syndrome 30.4 PRL INS IGF1 GNRH1
14 pituitary adenoma, prolactin-secreting 30.4 PRL IGF1 GNRH1
15 adenoma 30.4 PRL IGF1 CYP21A2 CRH
16 vaginal discharge 30.3 HP GNRH1 CYP19A1 CRP
17 uremia 30.3 LEP INS CRP
18 alopecia 30.2 SRD5A1 SHBG PRL IGF1
19 lipid metabolism disorder 30.2 SHBG LEP INS CYP21A2 CRP
20 polycystic ovary syndrome 30.2 SRD5A1 SHBG PRL LEP INS IGFBP1
21 insulin-like growth factor i 30.1 SHBG PRL LEP INS IGFBP1 IGF1
22 acanthosis nigricans 30.1 SHBG PRL LEP INS IGF1
23 pituitary adenoma 30.1 PRL IGF1 GNRH1 GHRL CRH
24 bone resorption disease 30.1 LEP INS IGF1 CYP19A1 CRP
25 hypothalamic disease 30.1 PRL LEP INS GNRH1 CRH
26 hyperinsulinism 30.0 SHBG LEP INS IGFBP1 IGF1 GNRH1
27 hypogonadism 30.0 SHBG PRL LEP INS IGF1 GNRH1
28 hyperglycemia 29.9 LEP INS IGF1 GHRL
29 hyperandrogenism 29.9 SRD5A1 SHBG PRL INS IGFBP1 IGF1
30 androgenic alopecia 29.8 SRD5A1 SHBG PRL INS IGF1 CYP19A1
31 gestational diabetes 29.8 SHBG LEP INS IGFBP1 IGF1 CRP
32 hypogonadotropic hypogonadism 29.7 SHBG PRL LEP INS GNRH1 FSHB
33 lipoid congenital adrenal hyperplasia 29.7 SRD5A1 SHBG PRL INS GNRH1 CYP21A2
34 amenorrhea 29.5 SHBG PRL LEP INS IGF1 GNRH1
35 glucose intolerance 29.3 SHBG LEP INS IGFBP1 IGF1 GHRL
36 anorexia nervosa 29.3 SHBG PRL LEP INS IGFBP1 IGF1
37 ovarian disease 29.1 SHBG PRL LEP INS IGFBP1 IGF1
38 premature ovarian failure 1 29.1 SHBG PRL INS IGF1 GNRH1 FSHR
39 diabetes mellitus, noninsulin-dependent 29.1 SHBG LEP INS IGFBP1 IGF1 GHRL
40 hypothyroidism 28.9 SHBG PRL LEP INS IGF1 GNRH1
41 body mass index quantitative trait locus 11 28.2 SHBG PRL LEP INS IGFBP1 IGF1
42 median arcuate ligament syndrome 10.6 CRP CGA
43 inhibited female orgasm 10.6 SHBG PRL
44 malignant otitis externa 10.6 INS CRP
45 secondary adrenal insufficiency 10.6 INS IGF1
46 neurogenic arthropathy 10.5 INS CRP
47 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.5 INS IGF1
48 postmenopausal atrophic vaginitis 10.5 SHBG CYP19A1
49 central precocious puberty 10.5 IGF1 GNRH1
50 kwashiorkor 10.5 SHBG INS CRP

Graphical network of the top 20 diseases related to Anovulation:



Diseases related to Anovulation
Sources

Symptoms & Phenotypes for Anovulation

About this section

GenomeRNAi Phenotypes related to Anovulation according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 9.55 IGF1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.55 IGF1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.55 BMP15
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.55 IGF1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-138 9.55 BMP15
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.55 IGF1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.55 IGF1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 9.55 BMP15
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.55 BMP15
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.55 IGF1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-21 9.55 IGF1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.55 BMP15 IGF1 SHBG
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.55 IGF1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-69 9.55 SHBG
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.55 IGF1

MGI Mouse Phenotypes related to Anovulation:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.3 AMHR2 BMP15 CGA CRH CYP19A1 FSHB
2 homeostasis/metabolism MP:0005376 10.28 AMHR2 CGA CRH CRP CYP19A1 FSHB
3 immune system MP:0005387 10.21 AMHR2 CRH CRP CYP19A1 CYP21A2 FSHR
4 hematopoietic system MP:0005397 10.17 AMHR2 CRH CYP19A1 CYP21A2 FSHR GNRH1
5 integument MP:0010771 10.06 AMHR2 CRH CYP19A1 CYP21A2 FSHR GNRH1
6 adipose tissue MP:0005375 10.02 CRH CYP19A1 FSHR GHRL IGF1 INS
7 liver/biliary system MP:0005370 9.86 CRH CYP19A1 GNRH1 HP IGFBP1 INS
8 neoplasm MP:0002006 9.76 AMHR2 FSHR GNRH1 HP IGF1 LEP
9 renal/urinary system MP:0005367 9.56 AMHR2 CRH CYP19A1 GNRH1 HP IGF1
10 reproductive system MP:0005389 9.4 AMHR2 BMP15 CGA CYP19A1 FSHB FSHR
Sources

Drugs & Therapeutics for Anovulation

About this section

Drugs for Anovulation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
3
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
4
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Menotropins Approved Phase 4 61489-71-2, 9002-68-0 5360545
8
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
9
leucovorin Approved Phase 4 58-05-9 6006 143
10
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
11
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
12
Drospirenone Approved Phase 4 67392-87-4 68873
13
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
14
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
15
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
16
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
18
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
19 Chelating Agents Phase 4
20 Anticoagulants Phase 4
21 Anti-Infective Agents Phase 4
22 Antidepressive Agents Phase 4
23 Psychotropic Drugs Phase 4
24 Calcium, Dietary Phase 4
25 carnitine Phase 4
26 Contraceptive Agents, Male Phase 4
27 Trace Elements Phase 4
28 Vitamins Phase 4
29 Nutrients Phase 4
30 Micronutrients Phase 4
31 Respiratory System Agents Phase 4
32 Antidotes Phase 4
33 Antioxidants Phase 4
34 Antiviral Agents Phase 4
35 Expectorants Phase 4
36 N-monoacetylcystine Phase 4
37 Protective Agents Phase 4
38 Pharmaceutical Solutions Phase 4
39 Hematinics Phase 4
40
Cyproterone Phase 4 2098-66-0 5284537
41 Calciferol Phase 4
42 Fenugreek Phase 4
43 Fenugreek seed meal Phase 4
44 Mineralocorticoids Phase 4
45 Mineralocorticoid Receptor Antagonists Phase 4
46 diuretics Phase 4
47 Diuretics, Potassium Sparing Phase 4
48 Cardiac Glycosides Phase 4
49 Glycoside Hydrolase Inhibitors Phase 4
50 Mitogens Phase 4

Interventional clinical trials:

(show top 50) (show all 196)
# Name Status NCT ID Phase Drugs
1 Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin Unknown status NCT03486626 Phase 4 Metformin
2 Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
3 Metformin for the Treatment of Unexplained Oligozspermia and Azoospermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
4 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
5 Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial Unknown status NCT02703649 Phase 4 Letrozole
6 Concomitant Clomiphene Citrate and Estradiol Versus Clomiphene Citrate Alone in Ovulation Induction: a Randomized Controlled Trial Unknown status NCT02186782 Phase 4 Clomiphene citrate and Estradiol;Clomiphene citrate and Placebo
7 Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
8 Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome Completed NCT00471523 Phase 4 Clomiphene citrate;Metformin
9 Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome Completed NCT03630341 Phase 4 Clomiphene Citrate 50mg;L-carnitine;Placebo Oral Tablet
10 Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility Completed NCT01250821 Phase 4 Menopur
11 Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome Completed NCT00795808 Phase 4 Metformin;Placebo;Metformin + Clomiphene;Metformin;Clomiphene
12 Double Blind Cross-over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome Completed NCT00478504 Phase 4 Letrozole;Clomifene citrate
13 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
14 Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial Completed NCT00558077 Phase 4 Metformin plus clomiphene citrate
15 Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin
16 Effects of Structured Exercise Program Versus Hypocaloric Hyperproteic Diet on the Reproductive Function in Obese Anovulatory Infertile Patients With Polycystic Ovary Syndrome: a 24-Week Prospective Study. Completed NCT00473538 Phase 4
17 The Effect of Metformin on Serum Insulin, Androgens and AMH in PCOS Patients Completed NCT02568488 Phase 4 Metformin
18 Therapeutic Effect of Vitamin D3 Supplementation to Clomiphene Citrate Resistant Polycystic Ovary Syndrome Women Completed NCT04010942 Phase 4 Vit D;Metformin;Clomiphene
19 N-acetyl Cysteine as an Adjuvant Therapy to Laparoscopic Ovarian Drilling in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine
20 Clomiphene Citrate Plus N-acetyl Cysteine Versus Clomiphene Citrate for Induction of Ovulation in Women With Newly Diagnosed Polycystic Ovary Syndrome: a Randomized Double-blind Controlled Trial Completed NCT01896492 Phase 4 NAC
21 Insulin Sensitivity After Metformin Suspension in Normal-Weight Women With Polycystic Ovary Syndrome Completed NCT00437333 Phase 4 Metformin cloridrate
22 Does Short-term Structured Exercise Training Program Plus Diet Intervention Improve Ovarian Sensitivity to Clomiphene Citrate in Polycystic Ovary Syndrome Patients (PCOS)? A Prospective Randomized Controlled Study Completed NCT01004068 Phase 4 Clomiphene citrate
23 The Effect of Endometrial Shedding With Medroxyprogesterone Acetate Prior to Ovulation Induction With Clomiphene Citrate in Oligo-ovulatory and Anovulatory Women: a Pilot Study Completed NCT02340013 Phase 4 Medroxyprogesterone acetate
24 A Phase IV, Open-label, Post Marketing, Prospective, Randomized, Controlled, Multicentre, Multinational Study to Investigate Tailoring of Recombinant FSH Use in Ovulation Stimulation Treatment in Chronic Anovulatory Subjects (WHO Group II) Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
25 Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
26 Comparison of Oral Contraceptive Versus Physical Exercise Effects on Cardiovascular and Metabolic Risk Factors in PCOS Women Completed NCT00593294 Phase 4 OC - Drospirenone plus Ethynylestradiol
27 Metformin vs. Acarbose Treatment in Infertile Overweight Women With PCOS: A Prospective Randomized Clinical Trial Completed NCT01279512 Phase 4 Metformin;Acarbose
28 Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial Completed NCT00679679 Phase 4 Metformin;Placebo
29 The Effects of Treatment With Oral Contraceptive Pill Containing Ethinyl Estradiol-Cyproterone Acetate and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in Polycystic Ovarian Syndrome Completed NCT02866786 Phase 4 Metformin;ethinyl estradiol and cyproterone acetate
30 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
31 Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS: a Randomized, 24-Week Study Completed NCT00463112 Phase 4 Sibutramine
32 The Effects of Vitamin D Supplementation on Transforming Growth Factor-beta1 and Vascular Endothelial Growth Factor in Vitamin D-Deficient Women With Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial Completed NCT02460380 Phase 4 Vitamin D3
33 Ovarian Function in Women With Polycystic Ovary Syndrome Recruiting NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
34 The Effect of Incremental Clomiphene Citrate(CC) Doses in Successive Induction Cycles on the Endogenous Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Steroid Hormone Responses to Treatment Recruiting NCT04210765 Phase 4 Clomiphene Citrate
35 Effect of Myo-Inositol- Based Co-treatment on Oocyte Quality in Women With Polycystic Ovarian Syndrome Undergoing Assisted Reproductive Technology Recruiting NCT03177122 Phase 4 Myo-inositol
36 Mild Stimulation Protocol Using Clomiphene Citrate / Gonadotropins Versus Conventional Stimulation Protocol for Women With PCOS Undergoing in Vitro Fertilization (IVF): a Prospective Non-randomized Controlled Trial Recruiting NCT04157725 Phase 4 mild stimulation protocol: oral Clomiphene Citrate;Conventional Stimulation Protocol: will receive FSH/HMG
37 Follicular Synchronization in Polycystic Ovarian Syndrome Patients Undergoing Intracytoplasmatic Sperm Injection With Letrozole /Antagonist Protocol: A Randomized Controlled Trial Recruiting NCT04069117 Phase 4 letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)
38 Continuous Versus Cyclical OCP Use in PCOS: A Pilot Study Recruiting NCT03819140 Phase 4 Yasmin
39 Can Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist Withstand When Administered at Different Points in the Menstrual Cycle? Not yet recruiting NCT04060992 Phase 4 Elagolix 200 MG Oral Tablet [Orilissa]
40 Pilot Study: Role of Dietary Fiber in PCOS Anovulation Terminated NCT00703092 Phase 4 Fiber-Stat
41 Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome Terminated NCT00159575 Phase 4 Metformin / Placebo treatment for 4 months
42 A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction Terminated NCT01871532 Phase 4 Gonal-f®
43 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
44 How Long Should First-line Treatment be Continued in Infertile PCOS Patients Who Ovulate Under Clomiphene Citrate? A Randomized Controlled Clinical Study. Withdrawn NCT00501839 Phase 4 clomiphene citrate
45 Tailored Versus Non-tailored Metformin Protocol for Ovulation Induction in Infertile Anovulatory PCOS Patients. A Randomized Controlled Clinical Study Withdrawn NCT00501787 Phase 4 Metformin
46 Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS) Unknown status NCT02305693 Phase 3 Letrozole
47 Comparison Between Laproscopic Ovarian Diathermy and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome: A Randomised Controlled Trial Unknown status NCT02304536 Phase 3 FSH
48 Phase 3 Study Investigating the Effect of Endobarrier Treatment on Fertility in Women With Polycystic Ovary Syndrome Unknown status NCT02255578 Phase 3 clomiphene citrate treatment
49 Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation Completed NCT02335879 Phase 3
50 A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction Using a Low-dose, Step-up Protocol in Chinese Females With WHO Group II Anovulatory Infertility Failing to Conceive on Clomiphene Citrate Completed NCT01923194 Phase 3 Highly Purified Urofollitropin;Recombinant Human Follitropin Alfa

Search NIH Clinical Center for Anovulation

Cochrane evidence based reviews: anovulation

Sources

Genetic Tests for Anovulation

About this section
Sources

Anatomical Context for Anovulation

About this section

MalaCards organs/tissues related to Anovulation:

40
Ovary, Pituitary, Breast, Testes, Liver, Endothelial, Thyroid
Sources

Publications for Anovulation

About this section

Articles related to Anovulation:

(show top 50) (show all 2636)
# Title Authors PMID Year
1
Decreased active, total and altered active to total ghrelin ratio in normal weight women with the more severe form of polycystic ovary syndrome. 61 54
20096985 2010
2
Different phenotypes of polycystic ovary syndrome by Rotterdam criteria are differently steroidogenic but similarly insulin resistant. 54 61
19782351 2010
3
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. 61 54
20091537 2010
4
Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. 61 54
19906783 2010
5
Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). 54 61
20092643 2010
6
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. 61 54
19821299 2009
7
Selective impairment in glycogen synthase kinase-3 and mitogen-activated protein kinase phosphorylation: comparisons with the hyperandrogenic and the hyperinsulinemic rats. 61 54
19027112 2009
8
A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. 54 61
19470707 2009
9
Androgen circle of polycystic ovary syndrome. 54 61
19279033 2009
10
WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome. 61 54
19588338 2009
11
The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. 54 61
19413702 2009
12
Transcriptional profiling with a pathway-oriented analysis identifies dysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome. 54 61
19141577 2009
13
Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal-weight women with PCOS with obesity and insulin resistance. 54 61
19243758 2009
14
Drug treatments for polycystic ovary syndrome. 61 54
19405411 2009
15
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. 54 61
19370625 2009
16
Polycystic ovary syndrome in the adolescent. 54 61
19344852 2009
17
PCOS and cancer risk. 54 61
20067879 2009
18
Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. 61 54
19212122 2009
19
Pancreatic beta-cells dysfunction in polycystic ovary syndrome. 54 61
19078872 2008
20
Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). 61 54
18505468 2008
21
Cardiovascular risk in women with polycystic ovary syndrome. 54 61
18799960 2008
22
Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. 61 54
18602948 2008
23
What every physician should know about polycystic ovary syndrome. 54 61
18844713 2008
24
Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. 61 54
18639784 2008
25
Ovulation triggers in anovulatory women undergoing ovulation induction. 54 61
18646175 2008
26
The role of mullerian inhibiting substance in female reproduction. 54 61
18460940 2008
27
Does polycystic ovary syndrome start in childhood? 54 61
18552753 2008
28
Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. 61 54
18382906 2008
29
A case of Cushing's syndrome presenting as endometrial hyperplasia. 54 61
18363281 2008
30
Structural evaluation of type 3 dopaminergic receptor gene (DRD3) in chronic anovulatory women. 61 54
18393218 2008
31
HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? 54 61
18729532 2008
32
Polycystic ovary syndrome in the Indian Subcontinent. 54 61
18181079 2008
33
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. 61 54
17984248 2007
34
Expression of leptin long-form receptor mRNA in luteinized granulosa cells of obese women with polycystic ovary syndrome. 61 54
17828512 2007
35
[Mechanism of action of insulin sensitizer agents in the treatment of polycystic ovarian syndrome]. 61 54
17547089 2007
36
Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. 54 61
17426408 2007
37
Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? 61 54
17145645 2006
38
Up-regulation of the phosphatidylinositol 3-kinase/protein kinase B pathway in the ovary of rats by chronic treatment with hCG and insulin. 54 61
16899578 2006
39
Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. 61 54
17185789 2006
40
The frequency of insulin resistance calculated upon the basis of a fasting glucose to insulin ratio and characteristics of insulin resistant women with polycystic ovary syndrome. 61 54
16985482 2006
41
Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. 61 54
16522691 2006
42
Metabolic effects of obesity on reproduction. 54 61
16790096 2006
43
Contributions of androgen and estrogen to fetal programming of ovarian dysfunction. 61 54
16606451 2006
44
Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. 54 61
16338908 2006
45
Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. 61 54
16263811 2006
46
Effect of leptin administration on ovulation in food-restricted rhesus monkeys. 54 61
17106186 2006
47
Polycystic ovary syndrome: the influence of environmental and genetic factors. 61 54
16728382 2006
48
Polycystic ovarian syndrome in Hong Kong Chinese women: patient characteristics and diagnostic criteria. 61 54
16219952 2005
49
[Polycystic ovary syndrome associated neoplasms]. 54 61
16444364 2005
50
Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. 54 61
15890737 2005
Sources

Variations for Anovulation

About this section
Sources

Expression for Anovulation

About this section
Search GEO for disease gene expression data for Anovulation.
Sources

Pathways for Anovulation

About this section

Pathways related to Anovulation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 65
Show member pathways
 13.39 PRL LEP GNRH1 GHRL FSHR FSHB
2
Prolactin Signaling Pathway 36 1
Show member pathways
 12.29 PRL LEP INS CGA
3
cAMP signaling pathway 36
12.13 GHRL FSHR FSHB CGA
4
Peptide hormone metabolism 65
Show member pathways
 11.99 LEP INS IGF1 GHRL FSHB CGA
5
G alpha (s) signalling events 65
11.87 FSHR FSHB CRH CGA
6
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.68 LEP INS IGF1
7
Metabolism of steroid hormones 65
Show member pathways
 11.61 SRD5A1 CYP21A2 CYP19A1 CGA
8
Steroid hormone biosynthesis 36
Show member pathways
 11.48 SRD5A1 CYP21A2 CYP19A1
9
Signaling events mediated by PTP1B 1
11.33 PRL LEP INS
10
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.26 IGF1 CYP19A1 CGA
11
Follicle Stimulating Hormone (FSH) signaling pathway 1
11.05 FSHR FSHB CYP19A1 CGA
12
Ovarian steroidogenesis 36
10.87 INS IGF1 FSHR FSHB CYP19A1 CGA
13
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.76 PRL LEP INS GHRL
14
Hormone ligand-binding receptors 65
10.37 GNRH1 FSHR FSHB CGA
Sources

GO Terms for Anovulation

About this section

Cellular components related to Anovulation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 SHBG PRL LOX LEP INS IGFBP1
2 extracellular space GO:0005615 9.47 PRL LOX LEP INS IGFBP1 IGF1
3 follicle-stimulating hormone complex GO:0016914 9.16 FSHB CGA

Biological processes related to Anovulation according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.16 INS GNRH1 GHRL FSHR FSHB CRH
2 signal transduction GO:0007165 10.07 PRL LEP INS IGFBP1 IGF1 GNRH1
3 positive regulation of gene expression GO:0010628 10.05 INS IGF1 FSHB CRP CRH
4 positive regulation of cell migration GO:0030335 9.96 INS IGF1 FSHB CGA
5 response to nutrient levels GO:0031667 9.81 PRL LEP GHRL
6 steroid biosynthetic process GO:0006694 9.8 SRD5A1 CYP21A2 CYP19A1
7 regulation of protein phosphorylation GO:0001932 9.8 LOX LEP FSHR
8 response to estrogen GO:0043627 9.79 SRD5A1 GHRL CRH
9 glucose metabolic process GO:0006006 9.78 LEP INS GHRL
10 hormone-mediated signaling pathway GO:0009755 9.77 GHRL FSHR FSHB
11 ovarian follicle development GO:0001541 9.72 FSHR FSHB BMP15
12 regulation of osteoclast differentiation GO:0045670 9.67 FSHR FSHB
13 hypothalamus development GO:0021854 9.67 SRD5A1 CRH
14 gonad development GO:0008406 9.66 FSHR CGA
15 adult feeding behavior GO:0008343 9.66 LEP GHRL
16 negative regulation of blood vessel diameter GO:0097756 9.65 INS CRP
17 acute-phase response GO:0006953 9.65 INS HP CRP
18 cellular protein metabolic process GO:0044267 9.65 PRL INS IGFBP1 IGF1 BMP15
19 negative regulation of lipid storage GO:0010888 9.64 LEP CRP
20 glucocorticoid biosynthetic process GO:0006704 9.64 CYP21A2 CRH
21 bone mineralization involved in bone maturation GO:0035630 9.6 LEP IGF1
22 Sertoli cell proliferation GO:0060011 9.58 FSHR FSHB
23 positive regulation of corticotropin secretion GO:0051461 9.58 GHRL CRH
24 female gonad development GO:0008585 9.58 FSHR CYP19A1 AMHR2
25 female genitalia development GO:0030540 9.57 SRD5A1 CYP19A1
26 androgen catabolic process GO:0006710 9.56 SRD5A1 CYP19A1
27 negative regulation of glucagon secretion GO:0070093 9.54 LEP CRH
28 positive regulation of cortisol secretion GO:0051464 9.52 GHRL CRH
29 follicle-stimulating hormone signaling pathway GO:0042699 9.51 FSHR FSHB
30 female gamete generation GO:0007292 9.5 FSHR FSHB BMP15
31 positive regulation of cell proliferation GO:0008284 9.5 PRL LEP INS IGF1 FSHB CRH
32 diterpenoid metabolic process GO:0016101 9.49 SRD5A1 CRH
33 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.46 GHRL CRH
34 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.46 LEP INS IGF1 FSHR
35 positive regulation of steroid biosynthetic process GO:0010893 9.43 FSHB CGA
36 female pregnancy GO:0007565 9.02 PRL LEP GNRH1 FSHB CRH

Molecular functions related to Anovulation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.28 PRL LEP INS IGF1 GNRH1 GHRL
2 follicle-stimulating hormone activity GO:0016913 8.96 FSHB CGA
Sources

Sources for Anovulation

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....